Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma

List of abbreviations ICI immune checkpoint inhibitor irAE immune-related adverse event IL-17A interleukin-17A AE adverse event The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanom...

Full description

Saved in:
Bibliographic Details
Published inCancer communications (London, England) Vol. 45; no. 1; pp. 56 - 57
Main Author Huang, Kai
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.01.2025
John Wiley and Sons Inc
Wiley
Subjects
Autoimmune diseases
Cancer
Conflicts of interest
Cytokines
Immunology
Immunotherapy
Lymphocytes
Melanoma
Monoclonal antibodies
Psoriasis
Research Highlights
Toxicity
Online AccessGet full text

Cover

More Information
Summary:List of abbreviations ICI immune checkpoint inhibitor irAE immune-related adverse event IL-17A interleukin-17A AE adverse event The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanoma. The ability to identify patients at risk for severe irAEs through biomarkers like IL-17A could enable more personalized treatment approaches. [...]the successful use of secukinumab in this context opens the door to broader clinical trials aimed at validating IL-17A as a therapeutic target, potentially leading to the development of new protocols for managing irAEs. [...]this study marks a significant advancement in the field of cancer immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2523-3548
2523-3548
DOI:10.1002/cac2.12628